title: [Risk factors of influenza (H1N1) 2009 hospitalization and effectiveness of pharmaceutical and nonpharmaceutical interventions in its prevention: a case-control study].
abstract: Potentially useful pharmaceutical measures to limit the impact of pandemic influenza in the community include antiviral drugs (neuraminidase inhibitors) and the influenza and pneumococcal vaccines, as influenza predisposes to bacterial pneumonia caused by Streptococcus pneumoniae. Non-pharmaceutical measures include hand washing and respiratory hygiene. Due to the lack of knowledge of the effectiveness of these measures in a pandemic situation, in September 2009, CIBER de Epidemiología y Salud Pública presented a multicenter case-control study, with controls matched for age, hospital and date of hospitalization, to investigate these aspects in 37 hospitals in 7 Spanish autonomous communities, in response to the call for research projects by the Ministry of Science and Innovation Research Program on Influenza A (H1N1) in Spain. For each confirmed hospitalized case of pandemic influenza, 1 confirmed outpatient case and 3 controls (2 hospitalized and 1 outpatient) were selected. Demographic variables, underlying medical conditions, use of antiviral agents, vaccines received and hygiene habits were collected for all cases and controls. In hospitalized cases, information on antiviral therapy and disease progression was collected. A total of 3750 patients were recruited by October 2010. Data cleansing and the recovery of variables is now underway. The involvement of the Public Health Directorate has been instrumental in adapting the project to the evolution of the pandemic.
authors.affiliation: CIBER de Epidemiología y Salud Pública, Departamento de Salud Pública, Universidad de Barcelona, c/ Casanova 143, Barcelona. angela.domínguez@ub.edu
authors.forename: Angela
authors.initials: A
authors.lastname: Domínguez
authors.forename: Jordi
authors.initials: J
authors.lastname: Alonso
authors.forename: Jenaro
authors.initials: J
authors.lastname: Astray
authors.forename: Maretva
authors.initials: M
authors.lastname: Baricot
authors.forename: Rafael
authors.initials: R
authors.lastname: Cantón
authors.forename: Jesús
authors.initials: J
authors.lastname: Castilla
authors.forename: Ady
authors.initials: A
authors.lastname: Castro
authors.forename: Miguel
authors.initials: M
authors.lastname: Delgado
authors.forename: Pere
authors.initials: P
authors.lastname: Godoy
authors.forename: Fernando
authors.initials: F
authors.lastname: González-Candelas
authors.forename: Vicente
authors.initials: V
authors.lastname: Martín
authors.forename: José María
authors.initials: JM
authors.lastname: Mayoral
authors.forename: José María
authors.initials: JM
authors.lastname: Quintana
authors.forename: Emilio
authors.initials: E
authors.lastname: Perea
authors.forename: Tomás
authors.initials: T
authors.lastname: Pumarola
authors.forename: Nuria
authors.initials: N
authors.lastname: Soldevila
authors.forename: Sonia
authors.initials: S
authors.lastname: Tamames
mesh_terms: D016022:Case-Control Studies; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype; D007251:Influenza, Human / Q000188:drug therapy / Q000517:prevention & control* / Q000628:therapy; D012307:Risk Factors; D013030:Spain